Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- kits assays measures measurements two 2 succinates dehydrogenases dehydrogenase/co-enzyme Q CoQ10 reductases sites electrons entry mitochondrial mitochondrias transports chains ETCs catalyzes oxidations fumarates reduces reductions ubiquinones ubiquinol QH2 oxygens O2 terminal steps respirations dysfunctions inhibits inhibitors inhibitions oncogenesis cancers inhibitory effects dehydrogenases atpenin A5 2-Thenoyltrifluoroacetone TTFA malonates isolates isolations DCPIP complexes rotenone antimycin A potassium cyanides KCN
- Product Overview:
Complex II (succinate dehydrogenase/co-enzyme Q reductase) is one of the major sites of electron entry into the mitochondrial electron transport chain (ETC). Complex II catalyzes the oxidation of succinate to fumarate, and in the process reduces ubiquinone (Q) to ubiquinol (QH2). Ultimately, oxidation of succinate will lead to reduction of O2, the terminal step in mitochondrial respiration. Cayman’s MitoCheck® Complex II Activity Assay allows for the activity of complex II to be determined without the need to isolate mitochondria or pre-incubate with antibodies. As complex II oxidizes succinate, electrons are passed to an analog of ubiquinone and then on to DCPIP, which, when oxidized, absorbs in the 600 nm range. The absorbance of DCPIP will decrease upon reduction. Thus, Complex II activity is measured as a decrease in absorbance at 600 nm over time. For the use of this kit with other types of tissue mitochondria, please see Cayman’s MitoCheck® Mitochondrial (Tissue) Isolation Kit (Item No. 701010).
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.